537 related articles for article (PubMed ID: 9466277)
61. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose.
Drobyski WR; Keever CA; Roth MS; Koethe S; Hanson G; McFadden P; Gottschall JL; Ash RC; van Tuinen P; Horowitz MM
Blood; 1993 Oct; 82(8):2310-8. PubMed ID: 8400284
[TBL] [Abstract][Full Text] [Related]
62. A potential graft-versus-leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: results from the French Bone Marrow Transplantation Society.
Espérou H; Boiron JM; Cayuela JM; Blanchet O; Kuentz M; Jouet JP; Milpied N; Cahn JY; Faucher C; Bourhis JH; Michallet M; Tanguy ML; Vernant JP; Gabert J; Bordigoni P; Ifrah N; Baruchel A; Dombret H;
Bone Marrow Transplant; 2003 May; 31(10):909-18. PubMed ID: 12748668
[TBL] [Abstract][Full Text] [Related]
63. Induction of graft-versus-host disease as immunotherapy of leukemia relapsing after allogeneic transplantation: single-center experience of 32 adult patients.
Mehta J; Powles R; Kulkarni S; Treleaven J; Singhal S
Bone Marrow Transplant; 1997 Jul; 20(2):129-35. PubMed ID: 9244416
[TBL] [Abstract][Full Text] [Related]
64. Predicting relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation by bcr-abl mRNA and DNA fingerprinting.
Okamoto R; Harano H; Matsuzaki M; Motomura S; Maruta A; Kodama F; Mohri H; Okubo T
Am J Clin Pathol; 1995 Nov; 104(5):510-6. PubMed ID: 7572810
[TBL] [Abstract][Full Text] [Related]
65. Molecular analysis of transient cytogenetic relapse after allogeneic bone marrow transplantation for chronic myeloid leukaemia.
Lin F; Kirkland MA; van Rhee FV; Chase A; Coulthard S; Bungey J; Goldman JM; Cross NC
Bone Marrow Transplant; 1996 Dec; 18(6):1147-52. PubMed ID: 8971386
[TBL] [Abstract][Full Text] [Related]
66. Presence of re-appearance of BCR-ABL-positive cells years after allogeneic bone marrow transplantation for chronic-phase chronic myelogenous leukemia in patients in hematological remission.
Diekmann L; Beelen DW; Quabeck K; Becher R; Schulte Holthausen H; Bützler R; Schaefer UW; Opalka B
Acta Haematol; 1994; 92(4):169-75. PubMed ID: 7701913
[TBL] [Abstract][Full Text] [Related]
67. Leukemia: management of relapse after allogeneic bone marrow transplantation.
Kumar L
J Clin Oncol; 1994 Aug; 12(8):1710-7. PubMed ID: 8040682
[TBL] [Abstract][Full Text] [Related]
68. Hematopoietic stem cell transplantation for T315I-mutated chronic myelogenous leukemia.
Basak G; Torosian T; Snarski E; Niesiobedzka J; Majewski M; Gronkowska A; Urbanowska E; Jedrzejczak W
Ann Transplant; 2010; 15(2):68-70. PubMed ID: 20657522
[TBL] [Abstract][Full Text] [Related]
69. Extramedullary tumors of myeloid blasts in adults as a pattern of relapse following allogeneic bone marrow transplantation.
Koc Y; Miller KB; Schenkein DP; Daoust P; Sprague K; Berkman E
Cancer; 1999 Feb; 85(3):608-15. PubMed ID: 10091734
[TBL] [Abstract][Full Text] [Related]
70. Lymphoblastoid human interferon and low dose IL-2 combined with donor lymphocyte infusion as therapy of a third relapse of CML--a case report.
Lönnqvist B; Brune M; Ljungman P
Bone Marrow Transplant; 1996 Jul; 18(1):241-2. PubMed ID: 8832027
[TBL] [Abstract][Full Text] [Related]
71. Donor lymphocyte infusion followed by interferon-alpha plus low dose cyclosporine A for modulation of donor CD3 cells activity with monitoring of minimal residual disease and cellular chimerism in a patient with first hematologic relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation.
Leda M; Ladon D; Pieczonka A; Boruczkowski D; Jólkowska J; Witt M; Wachowiak J
Leuk Res; 2001 Apr; 25(4):353-7. PubMed ID: 11248334
[TBL] [Abstract][Full Text] [Related]
72. Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients.
Radich JP; Gehly G; Gooley T; Bryant E; Clift RA; Collins S; Edmands S; Kirk J; Lee A; Kessler P
Blood; 1995 May; 85(9):2632-8. PubMed ID: 7727789
[TBL] [Abstract][Full Text] [Related]
73. The management of chronic myeloid leukaemia--a case history.
Sureda A; Hernández-Bronchud M
Ann Oncol; 1997 Jan; 8(1):91-6. PubMed ID: 9093713
[No Abstract] [Full Text] [Related]
74. Successful treatment of lymphoid blastic crisis in chronic myelogenous leukemia with the additional bcr/abl transcript using imatinib-combined chemotherapy and high-dose chemotherapy with allogeneic bone marrow stem cell transplantation.
Kawano N; Okuda S; Yoshida S; Kugimiya H; Ito M; Horikawa N; Chosa N; Hisakata T; Fukudome T; Sakurai R; Yamashita K; Ueda A; Kanda Y
Int J Hematol; 2011 Dec; 94(6):561-6. PubMed ID: 22057509
[TBL] [Abstract][Full Text] [Related]
75. Relapse after non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: early transplantation, use of an unrelated donor, and chronic graft-versus-host disease are protective.
Enright H; Davies SM; DeFor T; Shu X; Weisdorf D; Miller W; Ramsay NK; Arthur D; Verfaillie C; Miller J; Kersey J; McGlave P
Blood; 1996 Jul; 88(2):714-20. PubMed ID: 8695820
[TBL] [Abstract][Full Text] [Related]
76. Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation.
Lin F; van Rhee F; Goldman JM; Cross NC
Blood; 1996 May; 87(10):4473-8. PubMed ID: 8639810
[TBL] [Abstract][Full Text] [Related]
77. Alpha-interferon improves survival and remission duration in P-190BCR-ABL positive adult acute lymphoblastic leukemia.
Visani G; Martinelli G; Piccaluga P; Tosi P; Amabile M; Pastano R; Cavo M; Isidori A; Tura S
Leukemia; 2000 Jan; 14(1):22-7. PubMed ID: 10637472
[TBL] [Abstract][Full Text] [Related]
78. Percentage of Philadelphia chromosome (Ph)-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional-dose chemotherapy before collection of autologous cells.
Talpaz M; Kantarjian H; Liang J; Calvert L; Hamer J; Tibbits P; Durett A; Claxton D; Giralt S; Khouri I
Blood; 1995 Jun; 85(11):3257-63. PubMed ID: 7756658
[TBL] [Abstract][Full Text] [Related]
79. Minimal residual disease in patients with chronic myelogenous leukemia undergoing long-term treatment with recombinant interferon alpha-2b alone or in combination with interferon gamma.
Opalka B; Wandl UB; Becher R; Kloke O; Nagel-Hiemke M; Moritz T; Beer U; Seeber S; Niederle N
Blood; 1991 Nov; 78(9):2188-93. PubMed ID: 1932740
[TBL] [Abstract][Full Text] [Related]
80. Treatment with recombinant interferon (alpha-2b) early after bone marrow transplantation in patients at high risk for relapse [corrected].
Klingemann HG; Grigg AP; Wilkie-Boyd K; Barnett MJ; Eaves AC; Reece DE; Shepherd JD; Phillips GL
Blood; 1991 Dec; 78(12):3306-11. PubMed ID: 1742491
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
